Cargando…
Role of arformoterol in the management of COPD
Formoterol is a beta2-agonist that has both short and long acting bronchodilator effects. Beta2-agonists used as bronchodilators have been synthesized as racemates that comprise (R,R) and (S,S)-enantiomers. Compounds that are beta2-selective derive their bronchodilator effect from an interaction bet...
Autor principal: | King, Paul |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629977/ https://www.ncbi.nlm.nih.gov/pubmed/18990965 |
Ejemplares similares
-
Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
por: Ganapathy, Vaidyanathan, et al.
Publicado: (2017) -
One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD
por: Donohue, James F., et al.
Publicado: (2014) -
Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD
por: Bollu, Vamsi, et al.
Publicado: (2013) -
Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial
por: Donohue, James F, et al.
Publicado: (2018) -
Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment
por: Celli, Bartolome R, et al.
Publicado: (2019)